Millennium Management LLC Has $1.16 Million Holdings in Galapagos NV (NASDAQ:GLPG)

Millennium Management LLC lessened its holdings in Galapagos NV (NASDAQ:GLPG - Free Report) by 84.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,275 shares of the biotechnology company's stock after selling 225,079 shares during the period. Millennium Management LLC owned about 0.06% of Galapagos worth $1,163,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Galapagos during the fourth quarter worth about $26,000. American Century Companies Inc. grew its holdings in shares of Galapagos by 5.9% during the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after purchasing an additional 1,431 shares during the last quarter. QRG Capital Management Inc. grew its holdings in shares of Galapagos by 21.7% during the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 1,866 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Galapagos by 45.9% during the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock worth $247,000 after purchasing an additional 2,824 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Galapagos by 19.6% during the fourth quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company's stock worth $617,000 after purchasing an additional 3,684 shares during the last quarter. Institutional investors own 32.46% of the company's stock.

Galapagos Stock Performance

GLPG stock traded down $0.23 during trading on Friday, hitting $27.73. The company had a trading volume of 419,562 shares, compared to its average volume of 243,855. The business has a 50-day moving average of $26.35 and a 200-day moving average of $26.05. Galapagos NV has a one year low of $22.36 and a one year high of $31.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The company had revenue of $97.33 million during the quarter, compared to analyst estimates of $72.22 million. As a group, research analysts forecast that Galapagos NV will post -1.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Wall Street Zen cut Galapagos from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and reduced their target price for the company from $31.00 to $22.00 in a report on Friday, February 14th. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $25.33.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.